These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 8267674)
21. Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. Nagakura Y; Kadowaki M; Tokoro K; Tomoi M; Mori J; Kohsaka M J Pharmacol Exp Ther; 1993 May; 265(2):752-8. PubMed ID: 8496821 [TBL] [Abstract][Full Text] [Related]
22. Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography. Endo J; Nomura M; Morishita S; Uemura N; Inoue S; Kishi S; Kawaguchi R; Iga A; Ito S; Nakaya Y J Gastroenterol; 2002; 37(11):888-95. PubMed ID: 12483243 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activities of the optical isomers of (+/-)-4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl]benzamide (mosapride). Morie T; Kato S; Harada H; Yoshida N; Matsumoto J Chem Pharm Bull (Tokyo); 1994 Apr; 42(4):877-82. PubMed ID: 8020122 [TBL] [Abstract][Full Text] [Related]
24. 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs. Mikami T; Ochi Y; Suzuki K; Saito T; Sugie Y; Sakakibara M J Pharmacol Exp Ther; 2008 Apr; 325(1):190-9. PubMed ID: 18198343 [TBL] [Abstract][Full Text] [Related]
25. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys. Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675 [TBL] [Abstract][Full Text] [Related]
26. Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. Tsubouchi T; Saito T; Mizutani F; Yamauchi T; Iwanaga Y J Pharmacol Exp Ther; 2003 Aug; 306(2):787-93. PubMed ID: 12724347 [TBL] [Abstract][Full Text] [Related]
27. Effects of mosapride citrate, metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride citrate on equine gastric emptying, small intestinal and caecal motility. Okamura K; Sasaki N; Yamada M; Yamada H; Inokuma H Res Vet Sci; 2009 Apr; 86(2):302-8. PubMed ID: 18723200 [TBL] [Abstract][Full Text] [Related]
28. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide. Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167 [TBL] [Abstract][Full Text] [Related]
29. A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult. Matsuyoshi H; Kuniyasu H; Okumura M; Misawa H; Katsui R; Zhang GX; Obata K; Takaki M Neurogastroenterol Motil; 2010 Jul; 22(7):806-13, e226. PubMed ID: 20146727 [TBL] [Abstract][Full Text] [Related]
30. Investigation into the effects of mosapride on motility of Guinea pig stomach, ileum, and colon. Ji SW; Park HJ; Cho JS; Lim JH; Lee SI Yonsei Med J; 2003 Aug; 44(4):653-64. PubMed ID: 12950122 [TBL] [Abstract][Full Text] [Related]
32. Anti-emetic effect of mosapride citrate hydrate, a 5-HT4 receptor agonist, on selective serotonin reuptake inhibitors (SSRIs)-induced emesis in experimental animals. Mine Y; Oku S; Yoshida N J Pharmacol Sci; 2013; 121(1):58-66. PubMed ID: 23257657 [TBL] [Abstract][Full Text] [Related]
33. The synthesis and biological evaluation of a new bioactive metabolite of mosapride as a potential gastroprokinetic agent. Yao J; Li K; Song Y; He Z; Liu Z; Zhao L; Wang S Future Med Chem; 2019 Jan; 11(1):21-32. PubMed ID: 30526030 [TBL] [Abstract][Full Text] [Related]
34. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity. Cohen ML; Bloomquist W; Gidda JS; Lacefield W J Pharmacol Exp Ther; 1990 Jul; 254(1):350-5. PubMed ID: 2366187 [TBL] [Abstract][Full Text] [Related]
35. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. Matsunaga Y; Tanaka T; Yoshinaga K; Ueki S; Hori Y; Eta R; Kawabata Y; Yoshii K; Yoshida K; Matsumura T; Furuta S; Takei M; Tack J; Itoh Z J Pharmacol Exp Ther; 2011 Mar; 336(3):791-800. PubMed ID: 21123674 [TBL] [Abstract][Full Text] [Related]
36. RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo. Eglen RM; Lee CH; Smith WL; Johnson LG; Whiting RL; Hegde SS J Pharmacol Exp Ther; 1993 Aug; 266(2):535-43. PubMed ID: 8355189 [TBL] [Abstract][Full Text] [Related]
37. General pharmacological profile of the new cognition-enhancing agent nefiracetam. Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090 [TBL] [Abstract][Full Text] [Related]
38. The prokinetic effect of mosapride citrate on horse gastric emptying rates. Okamura K; Sasaki N; Fukunaka M; Yamada H; Inokuma H J Vet Med Sci; 2008 Jun; 70(6):627-8. PubMed ID: 18628607 [TBL] [Abstract][Full Text] [Related]
39. Pinacidil suppression on 5-HT3 receptor-mediated contraction of guinea pig ileum in vitro. Yuan YM; Xu DY; Hu GY Zhongguo Yao Li Xue Bao; 1998 Jan; 19(1):31-5. PubMed ID: 10375754 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Sakashita M; Yamaguchi T; Miyazaki H; Sekine Y; Nomiyama T; Tanaka S; Miwa T; Harasawa S Arzneimittelforschung; 1993 Aug; 43(8):867-72. PubMed ID: 8216445 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]